About BeiGene
BeiGene is a publicly listed company based in Cambridge (United States) founded in 2010 by John V Oyler. Targeted and immune-oncology drugs for cancer treatment are developed. BeiGene has raised $172 million across 6 funding rounds from investors including Merck, Amgen and Fidelity Investments. Its chief executive, as recorded, is John V Oyler. BeiGene offers products and services including Cancer Therapies. Its focus areas include Life Sciences, Oncology, Drugs and Diversified. Its legal entity is BeiGene, Ltd. Its competitors include Moderna, Incyte and Vir Biotechnology; 2 of its 3 listed competitors have raised funding.
Company details
Developer of targeted and immune-oncology drugs against cancer. The companys product pipeline includes oral small molecule inhibitors and monoclonal antibodies, such as BGB-3111, an oral inhibitor of Bruton tyrosine kinase, BGB-283, a B-RAF inhibitor; and BGB-290, a poly (ADP-ribose) polymerase inhibitor. Also, has another candidate BGB-108, a potentially differentiated PD-1 monoclonal antibody candidate.
- Total Equity Funding$172M (USD)
in 6 rounds
- Latest Funding Round$2.1B (USD), Post-IPO
Jul 2020
- InvestorsMerck
& 9 more
Products & Services of BeiGene
BeiGene offers a comprehensive portfolio of products and services, including Cancer Therapies.
Develops treatments for hematology and solid tumors via clinical trials
Apps and channels of BeiGene
its YouTube channel BeOne Medicines has 67.5K subscribers and 30 videos.
Videos from BeiGene
The most watched videos on BeiGene's YouTube channel, BeOne Medicines (67.5K subscribers). Click a video to play it here.
More on BeOne Medicines.
Funding Insights of BeiGene
BeiGene has successfully raised a total of $172M across 6 strategic funding rounds. The most recent funding activity was a Post-IPO round of $2.1 billion completed in July 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $172M
- Total Rounds 6
- Last Round Post-IPO — $2.1B
- Investors Count 10
All 6 funding rounds of BeiGene with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2020 | $2.1B | Post-IPO | – | – | |
| Oct 2019 | $2.8B | Post-IPO | – | – | |
| May 2015 | $97M | Series B | – | Hillhouse | |
| Nov 2014 | $75M | Series A | – | – | |
| Apr 2012 | Seed | – | – | ||
| May 2011 | Seed | – | – |
10 investors in total: 10 institutional.
Investors in BeiGene
BeiGene has secured backing from 10 investors, including institutional and venture fund investors. Prominent investors backing the company include Merck, Amgen and Fidelity Investments.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Early-stage and late-stage biotech and finance companies are funded. | rockspringscapital.com | Baltimore, United States | ||
Global private equity investments are managed with long-term focus. | hillhouseinvestment.com | New York, United States | ||
Acquisitions are targeted by CPE as a private equity firm. | cpe-fund.com | Beijing, China | ||
Biotech startups are funded by this venture capital firm. | boxercap.com | San Diego, United States | ||
Investment bank & PE fund focused on multiple sectors | jiuyoucapital.com.cn | |||
Developer of pharmaceutical products for treating multiple diseases | 1980 | amgen.com | Thousand Oaks, United States | |
Diversified asset management services are provided to investors globally. | 1937 | troweprice.com | Baltimore, United States | |
Provider of brokerage accounts, retirement planning, wealth management, and trading platforms | 1946 | fidelity.com | Boston, United States | |
Provides comprehensive infrastructure development services. | 2010 | zgcgroup.com.cn | Beijing, China | |
Pharmaceutical products are manufactured and marketed worldwide. | 1891 | merck.com | Kenilworth, United Kingdom |
Investor details for BeiGene
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of BeiGene
506 people are tracked at BeiGene (280 in leadership, 14 in board & advisors, 212 in team).
| Name | Role | Group |
|---|---|---|
John V Oyler | Founder & CEO | Leadership |
Nancy Lam | Vice President, Global Product Team Leader And Chief Of Staff, Solid Tumors | Leadership |
Xiaobin Wu | President & Chief Operating Officer | Leadership |
Adam Roach | SVP, Head of JAPAC | Leadership |
Tracy Guo | Associate Director, Talent Aquisition | Leadership |
Christopher Betts | Associate Director, Global TMF Management | Leadership |
Quting Zhang | Director | Leadership |
Bahar Akkoyun | Associate Director Global GMP QA - QMS | Leadership |
Graham Hardiman | Global Head of HR | Leadership |
Guo Wei | Senior Director | Leadership |
Kaifeng Lu | Senior Director | Leadership |
Katja Heikkiniemi | Associate Director, Field Innovation & Capabilities Lead ( Sub-region Europe) | Leadership |
Jennifer Morse | Associate Director, Global Portfolio & Program Management (gppm) - Hematology | Leadership |
Anand Reddi | VP, Global Strategic Initiatives & Corporate Operations, Chief of Staff to the CEO | Leadership |
Bruno Casimiro | Talent Development, Culture & Purpose, Head Europe & New Markets /hr BP Spain/portugal | Leadership |
Matthew Baran Pmp | Director Reporting And Analytics And Portfolio Management In Global Strategic Operations | Leadership |
Josie Walsh | Associate Director, Human Resources | Leadership |
Wouter B. van Berckel | Deputy QA Head Of Quality/ Consultant QP | Leadership |
Johann Dzinaku | Director, Clinical Product Quality, External Supply | Leadership |
Tricia Mullins | Executive Director, Global Head, Early Patient Engagement And Professional Societies (ex-china) | Leadership |
486 more people are available in the full profile.
Complete people profiles for BeiGene
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of BeiGene
4 dated milestones of BeiGene across 10 years, from founding to its latest funding, stage changes and deals.
- Founded BeiGene is founded.
- Funding First funding round.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $2.1B.
Competitors of BeiGene
BeiGene has 3 listed competitors in our database, 2 of them funded. They include Moderna, Incyte and Vir Biotechnology.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| incyte.com | 1991 | Wilmington, United States | 1,387 | Small molecules are developed for cancer and skin disease treatments. | ||
| vir.bio | 2017 | San Francisco, United States | $216M | 417 | Developer of therapeutics for the treatment of infectious diseases |
Detailed competitors of BeiGene
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of BeiGene
Websites that share an audience with BeiGene (beigene.com).
Websites whose visitors overlap most with BeiGene. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
beonemedicines.com | beonemedicines.com | 100% | #690,272 | – | |
| amoliindia.com | 86% | 1.6K | #7,590,126 | View details | |
| sunesis.com | 85% | View details | |||
discovery-insight.com | discovery-insight.com | 85% | – | ||
| centerwatch.com | 82% | 158.2K | #254,725 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 14 similar websites and full traffic analytics for BeiGene
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 14 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Immunology & Cancer Therapeutics
3 companies that operate in the same segment as BeiGene (Immunology & Cancer Therapeutics) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Targeted therapies for cancer treatment are developed. | 2005 | Waltham, Massachusetts, United States | USD 198.29 M | USD 172.35 M | 270 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Beigene
Complete news archive for BeiGene
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about BeiGene
BeiGene was founded in 2010 and raised its 1st funding round 1 year after it was founded.
BeiGene is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
John V Oyler is the CEO of BeiGene, as recorded in our data. They have also founded this company.
BeiGene is a funded company, having raised a total of $172M across 6 funding rounds to date.
Developer of targeted and immune-oncology drugs against cancer. The companys product pipeline includes oral small molecule inhibitors and monoclonal antibodies, such as BGB-3111, an oral inhibitor of Bruton tyrosine kinase, BGB-283, a B-RAF inhibitor; and BGB-290, a poly (ADP-ribose) polymerase inhibitor. Also, has another candidate BGB-108, a potentially differentiated PD-1 monoclonal antibody candidate.
BeiGene's top competitors include Moderna, Incyte and Vir Biotechnology.
BeiGene offers Cancer Therapies.
BeiGene has 10 investors. Key investors include Merck, Amgen, Fidelity Investments, T. Rowe Price, and Rock Springs Capital.
BeiGene operates through Beigene, Ltd..